Loading clinical trials...
Loading clinical trials...
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
Conditions
Interventions
Tislelizumab
Locations
2
China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Friendship Hospital
Beijing, Beijing Municipality, China
Start Date
March 16, 2024
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
January 13, 2026
NCT04703101
NCT05245786
NCT07038122
NCT07472868
NCT05876026
NCT05645094
Lead Sponsor
Beijing Friendship Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions